Association of lipid-lowering drugs with risk of sarcopenia: a drug target mendelian randomization study and meta-analysis
Authors:
Open Access
- 3 July 2024
- journal article
- research article
- Published by Springer Nature in Human Genomics
- Vol. 18 (1) , 1-12
Abstract
Background: Lipid-lowering drugs are widely used among the elderly, with some studies suggesting links to muscle-related symptoms. However, the causality remains uncertain. Methods: Using the Mendelian randomization (MR) approach, we assessed the causal effects of genetically proxied reduced low-density lipoprotein cholesterol (LDL-C) through inhibitions of hydroxy-methyl-glutaryl-CoA reductase (HMGCR), proprotein convertase subtilisin/kexin type 9 (PCSK9), and Niemann-Pick C1-like 1 (NPC1L1) on sarcopenia-related traits, including low hand grip strength, appendicular lean mass, and usual walking pace. A meta-analysis was conducted to combine the causal estimates from different consortiums. Results: Using LDL-C pooled data predominantly from UK Biobank, genetically proxied inhibition of HMGCR was associated with higher appendicular lean mass (beta = 0.087, P = 7.56 × 10− 5) and slower walking pace (OR = 0.918, P = 6.06 × 10− 9). In contrast, inhibition of PCSK9 may reduce appendicular lean mass (beta = -0.050, P = 1.40 × 10− 3), while inhibition of NPC1L1 showed no causal impact on sarcopenia-related traits. These results were validated using LDL-C data from Global Lipids Genetics Consortium, indicating that HMGCR inhibition may increase appendicular lean mass (beta = 0.066, P = 2.17 × 10− 3) and decelerate walking pace (OR = 0.932, P = 1.43 × 10− 6), whereas PCSK9 inhibition could decrease appendicular lean mass (beta = -0.048, P = 1.69 × 10− 6). Meta-analysis further supported the robustness of these causal associations. Conclusions: Genetically proxied HMGCR inhibition may increase muscle mass but compromise muscle function, PCSK9 inhibition could result in reduced muscle mass, while NPC1L1 inhibition is not associated with sarcopenia-related traits and this class of drugs may serve as viable alternatives to sarcopenia individuals or those at an elevated risk.Keywords
Funding Information
- National Natural Science Foundation of China (81601139)
- Natural Science Foundation of Hunan Province (2024JJ5576)
This publication has 40 references indexed in Scilit:
- Genomic Insights Into Statin Therapy: Differential Expression Analysis of Key GenesCurrent Problems in Cardiology, 2023
- Statin Intolerance: an Overview of US and International GuidanceCurrent Atherosclerosis Reports, 2023
- Uncovering the Relationship Between Statins and Muscle Problems in the ELSA-Brasil MSK CohortCardiovascular Drugs and Therapy, 2023
- Telomere Length and Development of Systemic Lupus Erythematosus: A Mendelian Randomization StudyArthritis & Rheumatology, 2022
- Statistical methods for Mendelian randomization in genome-wide association studies: A reviewComputational and Structural Biotechnology Journal, 2022
- Cholesterol absorption blocker ezetimibe prevents muscle wasting in severe dysferlin‐deficient and mdx miceJournal of Cachexia, Sarcopenia and Muscle, 2021
- Lipid Lowering Drugs: Present Status and Future DevelopmentsCurrent Atherosclerosis Reports, 2021
- Mendelian RandomizationJAMA, 2017
- Bias due to participant overlap in two‐sample Mendelian randomizationGenetic Epidemiology, 2016
- Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin IntoleranceJAMA, 2016